Story Health Eli Lilly

Lilly, Novo bet on amylin obesity drugs after GLP-1s

What to know

  • Photo illustration of a group of weight loss medications on a white background. Ucg | Universal Images Group | GettyS1
  • Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.S2
Timeline · newest first
1mo Wol

Lilly, Novo bet on amylin obesity drugs after GLP-1s

Photo illustration of a group of weight loss medications on a white background. Ucg | Universal Images Group | Getty

1mo Cnbc

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Lilly, Novo bet on amylin obesity drugs after GLP-1s

2 outlets 2 reports

What to know

  • Photo illustration of a group of weight loss medications on a white background. Ucg | Universal Images Group | GettyS1
  • Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.S2
Timeline · newest first

Sources · 2 citations

S1 Wol 1 report · EN
S2 CnbcLead 1 report · EN